GU Cancers 2025 | Which patients with urothelial carcinoma benefit the most from ADCs?
Salvador Jaime-Casas, MD, City of Hope Comprehensive Cancer Center, Duarte, CA, comments on the factors to consider when selecting patients for antibody-drug conjugates (ADCs) in the clinic. Depending on the design of the clinical trials, some evaluate ADCs as first-line treatment in previously untreated patients and others in heavily pre-treated populations who have undergone multiple lines of systemic therapy. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In this regard, we see that there is a variety of designs across clinical trials. Some of these evaluate antibody drug conjugates in patients who are receiving this as a first-line treatment in previously untreated patients. However, some others are evaluating this in heavily pretreated patient populations who have already undergone different lines of systemic therapy, including platinum-based chemotherapy...
In this regard, we see that there is a variety of designs across clinical trials. Some of these evaluate antibody drug conjugates in patients who are receiving this as a first-line treatment in previously untreated patients. However, some others are evaluating this in heavily pretreated patient populations who have already undergone different lines of systemic therapy, including platinum-based chemotherapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
